Results Daprodustat three times weekly was noninferior to epoetin for mean change in
hemoglobin (model-adjusted mean treatment difference [daprodustat-epoetin],− 0.05; 95 …

Background: Daprodustat is an oral agent that stimulates erythropoiesis by inhibiting the
prolyl hydroxylases which mark hypoxia-inducible factor for degradation through …

Results Of 332 participants screened, 271 participants were randomized (safety evaluation:
271 participants; efficacy evaluation: 267 intent-to-treat population). The mean hemoglobin …

Background: A phase 3 study to assess the efficacy and safety of the desidustat, an oral
hypoxia-inducible factor prolyl hydroxylase inhibitor, against the epoetin alfa for the …

Importance Daprodustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, is being
evaluated as an oral alternative to conventional erythropoiesis-stimulating agent (ESA) …

Daprodustat, one of several oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-
PHIs) that have undergone clinical trials for the treatment of anemia in people with CKD on …

Background This study evaluated the hemoglobin dose response, other efficacy measures
and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl …

Background Concerns regarding cardiovascular safety with current treatments for anemia in
patients with dialysis-dependent (DD)-CKD have encouraged the development of …

Background Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase
inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin …

Background Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor currently
being investigated as a treatment for anemia of chronic kidney disease (CKD) in both …